Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Parker

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Contemporary Clinical Trials|October 10, 2020
A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BPLinnea A Polgreen, Barry L Carter, Philip M Polgreen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerJohann S de Bono, Howard I Scher, R Bruce Montgomery, et al.
European Urology|June 27, 2016
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA TrialChristopher Parker, Steven E Finkelstein, Jeff M Michalski, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
DNA Repair|December 10, 2024
Corrigendum to "BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination" [DNA Repair 115 (2022) 103331]Christopher Parker, Adam C Chambers, Dustin J Flanagan, et al.
DNA Repair|April 25, 2022
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombinationChristopher Parker, Adam C Chambers, Dustin J Flanagan, et al.
Brain : a Journal of Neurology|June 27, 2022
Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genesPeter McColgan, Sarah Gregory, Paul Zeun, et al.
Clinical Genitourinary Cancer|October 2, 2012
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesSten Nilsson, Lars Franzén, Christopher Parker, et al.
The Lancet. Oncology|June 5, 2007
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studySten Nilsson, Lars Franzén, Christopher Parker, et al.
Journal of Substance Use and Addiction Treatment|October 22, 2023
A smoking cessation intervention for rural veterans tailored to individual risk factors: A multicenter randomized clinical trialMark W Vander Weg, M Bryant Howren, Kathleen M Grant, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Contemporary Clinical Trials|October 10, 2020
A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BPLinnea A Polgreen, Barry L Carter, Philip M Polgreen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerJohann S de Bono, Howard I Scher, R Bruce Montgomery, et al.
European Urology|June 27, 2016
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA TrialChristopher Parker, Steven E Finkelstein, Jeff M Michalski, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
DNA Repair|December 10, 2024
Corrigendum to "BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination" [DNA Repair 115 (2022) 103331]Christopher Parker, Adam C Chambers, Dustin J Flanagan, et al.
DNA Repair|April 25, 2022
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombinationChristopher Parker, Adam C Chambers, Dustin J Flanagan, et al.
Brain : a Journal of Neurology|June 27, 2022
Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genesPeter McColgan, Sarah Gregory, Paul Zeun, et al.
Clinical Genitourinary Cancer|October 2, 2012
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesSten Nilsson, Lars Franzén, Christopher Parker, et al.
The Lancet. Oncology|June 5, 2007
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studySten Nilsson, Lars Franzén, Christopher Parker, et al.
Journal of Substance Use and Addiction Treatment|October 22, 2023
A smoking cessation intervention for rural veterans tailored to individual risk factors: A multicenter randomized clinical trialMark W Vander Weg, M Bryant Howren, Kathleen M Grant, et al.
Pageof 8